SoCalBio

  • Immunis Chairman Dr. Hans Keirstead is an Invited Speaker at the 2024 Brain Trust Conference
    on February 23, 2024

    IRVINE, Calif.--(BUSINESS WIRE)-- #ClinicalTrials--Immunis, Inc., a private biotech company revolutionizing cellular secretome therapeutics, is proud to announce that its Chairman, Dr. Hans Keirstead, will present at the exclusive 13D Brain Trust Conference in the Bahamas. Brain Trust is a highly exclusive, invite-only event covering artificial intelligence, global technological advancements, innovative biotechnology, and unique investment opportunities. Like its name, the Brain Trust Conference invites the worl

  • Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
    on February 23, 2024

    IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:30 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. A

  • Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
    on February 22, 2024

    LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO and President Alan Auerbach will participate in a Breast & Lung Cancer panel on 3/6/24 at TD Cowen's Health Care Conference .

  • Caldera Medical's Humanitarian Effort Reaches New Heights: 400,000 Women Treated Worldwide
    on February 22, 2024

    LOS ANGELES--(BUSINESS WIRE)-- #calderamedical--Caldera Medical, renowned for its dedication to improving the quality of life for women, has announced significant milestones in its global humanitarian program. In partnership with surgeons worldwide, the initiative revolutionizes women's healthcare, especially in underserved regions. Since the program's expansion in 2016, Caldera Medical has embarked on 296 missions across 56 countries, treating over 400,000 women. These missions have not just been about providin

  • Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
    on February 21, 2024

    ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023. Key highlights include: Record net sales of $82.4 million in Q4 2023 increased 16% year-over-year on a reported basis and 15% year-over-year on a constant currency basis. Gl

  • ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
    on February 21, 2024

    CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that enrollment and initial follow-up has been completed for the safety portions of a clinical trial that is studying ImmunityBio’s investigational cancer vaccine of a tri-valent combination of antigens delivered by a second-generation Adenovirus vector (Tri-Ad5 CEA/MUC1/brachyury) together with its IL-15 superagonist N-803 for participants with Lynch syndrome. The study, sp

  • jCyte, Inc. Announces Positive Pre-Phase 3 FDA Type B Meeting and Outlines Plans to Start Pivotal Trial of jCell® for Retinitis Pigmentosa in the Second Half of 2024
    on February 21, 2024

    NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- #RP--jCyte, Inc., a pioneering biotechnology company dedicated to preserving and restoring vision in patients with retinitis pigmentosa (RP) and other degenerative retinal disorders, is pleased to announce the successful outcome of its pre-phase 3 Type B meeting with the US Food and Drug Administration (FDA) held on January 16, 2024. Additionally, the company is gearing up to commence its pivotal US trial for jCell in the second half of 2024. John Sholar, Chie

  • ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
    on February 21, 2024

    LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex

  • Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
    on February 20, 2024

    PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2023 after the market closes on Tuesday, February 27, 2024. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss financial results, provide a

  • BiVACOR® Receives $13 Million to Support Clinical Trials for the Company’s Total Artificial Heart
    on February 20, 2024

    GOLD COAST, Australia & HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--BiVACOR®, a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements. Led by Monash University, the AHFP is comprised of a consortium of research centers in Australia in collaboration with BiVACO

  • STAAR Surgical to Report Fourth Quarter Results on February 26, 2024
    on February 19, 2024

    LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the fourth quarter ending December 29, 2023, on Monday, February 26, 2024, after the market close. STAAR will host a conference call and webcast on Monday, February 26 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to dis

  • Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
    on February 15, 2024

    LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PT on Feb. 29 to discuss its fourth quarter and full year 2023 earnings results.

  • Simulations Plus Extends Collaboration with Major Toxicology Research Agency
    on February 15, 2024

    LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced an extension to its agreement with the NIEHS Division of Translational Toxicology to support their research efforts.

  • Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
    on February 14, 2024

    THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced its recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosu

  • Dermavant Submits Supplemental New Drug Application (sNDA) to FDA for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
    on February 14, 2024

    LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Submits Supplemental New Drug Application to FDA for VTAMA® Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children

  • Simulations Plus Launches Corporate Development Initiative
    on February 13, 2024

    LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced the launch of a corporate development initiative to pursue strategic investments in early-stage technology companies.

  • Masimo Announces the First FDA-cleared “Over-the-Counter” Fingertip Pulse Oximeter
    on February 13, 2024

    IRVINE, Calif.--(BUSINESS WIRE)--Masimo MightySat® Medical has received FDA clearance, making it the first and only FDA-cleared medical fingertip pulse oximeter available OTC.

  • Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
    on February 13, 2024

    LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that it had initiated ALISCA-Lung1, a Phase II clinical trial of alisertib in small cell lung cancer.

  • Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024
    on February 13, 2024

    EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 28, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the res

  • New Peer-Reviewed Study Finds That Masimo SET® Pulse Oximetry Measures Accurately on Both Black and White People Even During Low Perfusion
    on February 8, 2024

    IRVINE, Calif.--(BUSINESS WIRE)--A new study has found that Masimo RD SET® pulse oximetry sensors accurately measure SpO2 on both Black and White subjects even when perfusion is low.

  • Biocom California Appoints New Members to its Board of Governors
    on February 7, 2024

    SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO--(BUSINESS WIRE)--Biocom California, the association representing the California life science industry, today announced that it appointed Jeffrey Hessekiel, executive vice president and general counsel at Exelixis, and Michael Boss, senior vice president at Alexandria Real Estate Equities, to its board of governors. “Mr. Hessekiel and Mr. Boss are valuable additions to our board of governors, which consists of prominent life science leaders

  • TigerConnect is a 2024 Best in KLAS Award Winner for Clinical Communications
    on February 7, 2024

    SANTA MONICA, Calif.--(BUSINESS WIRE)--TigerConnect, healthcare's most trusted clinical collaboration platform, today proudly announced its Clinical Collaboration Platform is a 2024 Best in KLAS winner for Clinical Communication Ambulatory/Post-Acute Care. The Best in KLAS Award is a benchmark of excellence in the healthcare technology industry, distinguishing software and services that significantly impact healthcare delivery and patient care. All rankings are a direct result of the feedback f

  • AHF Hammers Gilead Over Continued Profiteering
    on February 7, 2024

    LOS ANGELES--(BUSINESS WIRE)--AHF Hammers Gilead Over Continued Profiteering

  • Edwards Lifesciences Reports Fourth Quarter Results
    on February 6, 2024

    IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook Q4 sales grew 14 percent to $1.53 billion; constant currency1 sales grew 13 percent Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent Q4 EPS of $0.61; adjusted1 EPS of $0.64 2023 sales of $6.0 billion grew 12 percent; EPS of $2.30; adjusted EPS of $2.51 Completed enrollment early in PROGRESS pivotal trial, studying

  • Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
    on February 6, 2024

    PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 first quarter ended December 31, 2023. The Company is hosting a conference call today, February 6, 2024, at 4:30 p.m. ET to discuss the results. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. A replay of the webcast will be available approximately two hours

  • KARL STORZ unifies its US organizations under a central management team, Sonal Matai named US President
    on February 6, 2024

    EL SEGUNDO, Calif.--(BUSINESS WIRE)--Three separate KARL STORZ subsidiaries are merging to form a single unified organization, consolidating R&D, manufacturing, and commercial operations.

  • Simulations Plus to Participate in Upcoming Healthcare Conferences
    on February 6, 2024

    LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will be participating in Oppenheimer's 34th Annual Healthcare Life Sciences Conference and BTIG at Snowbird on February 13-14, 2024.

  • ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
    on February 5, 2024

    CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that findings from Patient-Reported Outcomes (PROs) of participants in the phase 2/3 QUILT 3.032 study of N-803 plus BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) were published by the peer-reviewed journal Urology Practice. These PROs support the positive interim results from the study published in NEJM Evidence, wherein 71% of patients in cohort

  • Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
    on February 2, 2024

    IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR). The EVOQUE system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate

  • Agendia Announces First Patient Enrolled in DEBRA Trial Using MammaPrint®
    on February 1, 2024

    IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia®, Inc., announced today that the first patient to use MammaPrint® as an enrollment biomarker for the DEBRA Trial is to be enrolled. The Phase III NRG Oncology De-Escalation of Breast Radiation (DEBRA) Trial (NCT04852887) is a clinical study looking at safely reducing the use of breast radiation after lumpectomy for people with low-risk, early-stage breast cancer. The DEBRA trial will seek to determine if, in comparison to the usual treatment

  • Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
    on January 31, 2024

    THOUSAND OAKS, Calif. & CASTRES, France--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, and Pierre Fabre Laboratories, a global player in oncology and responsible for worldwide commercialization of tabelecleucel (tab-cel® or EBVALLO™), today announced that data from the pivotal Phase 3 ALLEL

  • Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21
    on January 31, 2024

    ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2023 financial results after the market close on Wednesday, February 21, 2024. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 2

  • Syphilis Soars: AHF Urges Congress to Boost Prevention Funding
    on January 30, 2024

    LOS ANGELES--(BUSINESS WIRE)-- #CongenitalSyphilis--With alarmingly high rates of preventable syphilis and congenital syphilis skyrocketing to nearly 20% higher than in 2023, AIDS Healthcare Foundation (AHF) urges U.S. Congress to reverse proposed cuts and increase funding for sexually transmitted infection prevention programs and improved access to testing and treatment. “Sexually transmitted infections, including syphilis, are at an all-time high for the sixth consecutive year, yet budgets for these programs are b

  • Simulations Plus Releases GastroPlus® Version 9.9
    on January 30, 2024

    LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the release of GastroPlus version 9.9 with key enhancements from FDA collaborations, client feedback, and current research.

  • Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
    on January 30, 2024

    SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene ciloleucel). With this approval, Kite’s median turnaround time (TAT) in the U.S. is anticipated to be reduced from 16 days to 14 days. Median TAT is defined as time from leukapheresis, when a patient’s T cells are collected, to product releas

  • Edwards Lifesciences to Host Earnings Conference Call on February 6, 2024
    on January 30, 2024

    IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwar

  • CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    on January 30, 2024

    IRVINE, Calif.--(BUSINESS WIRE)--CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  • ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
    on January 26, 2024

    LOS ANGELES--(BUSINESS WIRE)---- $CDXC #IR--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners 2024 Investor Select Conference. Mr. Fried and Mrs. Gerber will participate in virtual one-on-one meetings throughout the event on Thursday, February 1, 2024. To arrange a meeting with the Chrom

  • Endologix Announces that Art Taylor Joins Board of Directors
    on January 25, 2024

    IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that Art Taylor has been appointed to the Endologix Board of Directors. Art Taylor has over 30 years of experience in operational and financial executive leadership within the medical device, pharmaceutical, and high-tech industries. Mr. Taylor’s expertise extends to both publicly

  • City of Hope, TGen Researchers Develop Machine-Learning Tool to Detect Cancer Earlier via Liquid Biopsy
    on January 24, 2024

    LOS ANGELES--(BUSINESS WIRE)--Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, and Translational Genomics Research Institute (TGen), a precision medicine research organization that is part of City of Hope, have developed and tested an innovative machine-learning approach that could one day enable the earlier detection of cancer in patients by using smaller blood draws. The study was published today in the journal Science Translati

  • Integrated Endoscopy Partners with Frii Medical to Market Wireless, Single-Use Shaver System
    on January 24, 2024

    IRVINE, Calif.--(BUSINESS WIRE)-- #arthroscopy--Integrated Endoscopy, a medical device company pioneering the development of cordless 4K, low-cost, single-use endoscopes for the arthroscopic surgery market, has announced its partnership with Frii Medical to bring its proprietary single-use shaver system to the global market. The first-of-its-kind wireless shaver offers surgeons and health centers the freedom to operate efficiently in any operating room setting, eliminating power cords to the controller. The s

  • STAAR Surgical Announces Strategic Agreement in U.S. with SharpeVision
    on January 23, 2024

    LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, and SharpeVision, a premier ophthalmology group with clinics in Seattle, Chicago and Austin, today announced a strategic agreement to provide EVO ICL lenses as a first choice for patients seeking visual freedom from contact lenses and glasses. STAAR Surgical and SharpeVisio

  • Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
    on January 22, 2024

    PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal first quarter ended December 31, 2023. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. A replay of the webcast will be available approximately two hours after the co

  • Masimo Announces Reinstatement of Import Ban on Infringing Apple Watches
    on January 17, 2024

    IRVINE, Calif.--(BUSINESS WIRE)--The Federal Circuit has lifted the temporary stay on the import ban of certain Apple Watch models.

  • Masimo Announces New Member of the Board of Directors
    on January 16, 2024

    IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that Bob Chapek has been appointed to Masimo’s Board of Directors. Mr. Chapek was Chief Executive Officer of The Walt Disney Company, one of the world’s largest media and entertainment companies, from February 2020 to November 2022, successfully leading Disney through the global COVID-19 pandemic and recovery. Under his leadership, Disney strategically realigned its media and entertainment divisions, expanded the scale and g

  • Sensydia Completes Fifth Study for Heart-Sound AI
    on January 16, 2024

    LOS ANGELES--(BUSINESS WIRE)--Non-invasive cardiac assessment company Sensydia announced today that it has completed its 50-subject development study at the University of Minnesota (UMN). This study was conducted at UMN to collect data for its innovative AI-powered, non-invasive Cardiac Performance System (CPS™) that uses heart sound analysis to enable earlier detection and more effective therapy guidance for patients suffering from heart failure and pulmonary hypertension. Sensydia is developi

  • Sonendo to Participate at Upcoming Investor Conference
    on January 16, 2024

    LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. (OTCQX: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that management will participate in the Sidoti Virtual Micro-Cap Conference. Management is scheduled to present on Wednesday, January 17th at 1:00 p.m. Pacific Time/4:00 p.m. Eastern Time. A webcast of the presentation will be available on the “Investors” section of the company’s website at: investor.sonendo.com. About Sonendo Sonendo i

  • Reflow Medical Receives CE Mark for Bare Temporary Spur Stent System for Treating de novo or Restenotic Below-the-Knee (BTK) Lesions
    on January 16, 2024

    SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- #CEMark--Reflow Medical, Inc. receives CE (Conformité Européenne) Mark certification in the European Union for the Bare Temporary Spur Stent System.

  • Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
    on January 11, 2024

    LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO and President of Puma Biotechnology, will present an update on Puma Biotechnology at the B. Riley Oncology Conf. on Jan. 18, 2024.

  • “The Time is Now” to Maximize Human Healthspan: A Discussion with Peter Diamandis, Hans Keirstead, Daniel Kraft and Jane Metcalfe
    on January 11, 2024

    IRVINE, Calif.--(BUSINESS WIRE)-- #ClinicalTrials--Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, presents a one-of-a-kind film (The Time is Now) with world-renowned longevity innovators who examine the future of aging and human healthspan. Immunis was honored to host esteemed interviewees Dr. Peter Diamandis, Dr. Hans Keirstead, Dr. Daniel Kraft, and Jane Metcalfe, who all share the common goal of revolutionizing human health. With ov